Found: 3
Select item for more details and to access through your institution.
Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 7, p. 805, doi. 10.1093/jnci/djad072
- By:
- Publication type:
- Article
Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited.
- Published in:
- Journal of Molecular Medicine, 2017, v. 95, n. 3, p. 239, doi. 10.1007/s00109-016-1494-0
- By:
- Publication type:
- Article
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00568-5
- By:
- Publication type:
- Article